Citation tools
"A Phase I, First-in-Human, Healthy Volunteer Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CVN424, a Novel G Protein-Coupled Receptor 6 Inverse Agonist for Parkinson’s Disease." Journal of Pharmacology and Experimental Therapeutics
381.1
(2022):
33-41.
Web. 28 Mar. 2024.